159 related articles for article (PubMed ID: 29991401)
1. Economic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regions.
Nam VX; Nhung NV; Hoa NB; Thuy HTT; Phuong NTM; Anh NT; Anh LTN; Trung VQ; Ha TV; Meeyai A; Thavorncharoensap M; Chaikledkaew U
Int J Tuberc Lung Dis; 2018 Aug; 22(8):912-917. PubMed ID: 29991401
[TBL] [Abstract][Full Text] [Related]
2. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
3. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan.
van den Hof S; Collins D; Hafidz F; Beyene D; Tursynbayeva A; Tiemersma E
BMC Infect Dis; 2016 Sep; 16(1):470. PubMed ID: 27595779
[TBL] [Abstract][Full Text] [Related]
4. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
[TBL] [Abstract][Full Text] [Related]
5. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Laurence YV; Griffiths UK; Vassall A
Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
[TBL] [Abstract][Full Text] [Related]
6. Determinants of catastrophic costs among households affected by multi-drug resistant tuberculosis in Ho Chi Minh City, Viet Nam: a prospective cohort study.
Pham TAM; Forse R; Codlin AJ; Phan THY; Nguyen TT; Nguyen N; Vo LNQ; Dat PT; Minh HDT; Nguyen LH; Nguyen HB; Nguyen NV; Bodfish M; Lönnroth K; Wingfield T; Annerstedt KS
BMC Public Health; 2023 Dec; 23(1):2372. PubMed ID: 38042797
[TBL] [Abstract][Full Text] [Related]
7. Cost of treatment for multidrug-resistant tuberculosis in South Korea.
Kang YA; Choi YJ; Cho YJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Respirology; 2006 Nov; 11(6):793-8. PubMed ID: 17052310
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
Alemayehu S; Yigezu A; Hailemariam D; Hailu A
PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
[TBL] [Abstract][Full Text] [Related]
9. Catastrophic costs incurred by tuberculosis affected households from Thailand's first national tuberculosis patient cost survey.
Youngkong S; Kamolwat P; Wongrot P; Thavorncharoensap M; Chaikledkaew U; Nateniyom S; Pungrassami P; Praditsitthikorn N; Mahasirimongkol S; Jittikoon J; Nishikiori N; Baena IG; Yamanaka T
Sci Rep; 2024 May; 14(1):11205. PubMed ID: 38755216
[TBL] [Abstract][Full Text] [Related]
10. Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria.
Musa BM; John D; Habib AG; Kuznik A
Trop Med Int Health; 2016 Feb; 21(2):176-82. PubMed ID: 26610176
[TBL] [Abstract][Full Text] [Related]
11. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
[TBL] [Abstract][Full Text] [Related]
12. Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa.
Ramma L; Cox H; Wilkinson L; Foster N; Cunnama L; Vassall A; Sinanovic E
Int J Tuberc Lung Dis; 2015 Dec; 19(12):1513-9. PubMed ID: 26614194
[TBL] [Abstract][Full Text] [Related]
13. Cost of three models of care for drug-resistant tuberculosis patients in Nigeria.
Bada FO; Okpokoro E; Blok N; Meribole E; Dutt S; Dakum P; Abimiku A; Zwerling A; Kik SV
BMC Infect Dis; 2019 Jan; 19(1):41. PubMed ID: 30630429
[TBL] [Abstract][Full Text] [Related]
14. Cost of multidrug resistant tuberculosis in Germany-An update.
Diel R; Sotgiu G; Andres S; Hillemann D; Maurer FP
Int J Infect Dis; 2021 Feb; 103():102-109. PubMed ID: 33157286
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol.
Gama E; Madan J; Langley I; Girma M; Evans D; Rosen S; Squire SB
BMJ Open; 2016 Oct; 6(10):e014386. PubMed ID: 27798041
[TBL] [Abstract][Full Text] [Related]
16. Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?
Berhanu RH; Schnippel K; Kularatne R; Firnhaber C; Jacobson KR; Horsburgh CR; Lippincott CK
Int J Tuberc Lung Dis; 2018 Aug; 22(8):358-362. PubMed ID: 29991400
[TBL] [Abstract][Full Text] [Related]
17. Measuring catastrophic costs due to tuberculosis in Viet Nam.
Nhung NV; Hoa NB; Anh NT; Anh LTN; Siroka A; Lönnroth K; Garcia Baena I
Int J Tuberc Lung Dis; 2018 Sep; 22(9):983-990. PubMed ID: 30092862
[TBL] [Abstract][Full Text] [Related]
18. Tuberculosis care strategies and their economic consequences for patients: the missing link to end tuberculosis.
Getahun B; Wubie M; Dejenu G; Manyazewal T
Infect Dis Poverty; 2016 Nov; 5(1):93. PubMed ID: 27799063
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011.
Nguyen HB; Nguyen NV; Tran HT; Nguyen HV; Bui QT
Western Pac Surveill Response J; 2016; 7(2):35-40. PubMed ID: 27508089
[TBL] [Abstract][Full Text] [Related]
20. Costs of providing tuberculosis diagnosis and treatment services in Viet Nam.
Minh HV; Mai VQ; Nhung NV; Hoi LV; Giang KB; Chung LH; Kien VD; Duyen NT; Ngoc NB; Anh TT; Phuong TB; Ngan TT; Khanh PH
Int J Tuberc Lung Dis; 2017 Sep; 21(9):1035-1040. PubMed ID: 28826454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
